Tag: selpercatinib

September 9, 2019 Off

Lilly soon seeks regulatory approval for RET fusion-positive NSCLC treatment

By Dino Mustafić

Eli Lilly’s test of oral selpercatinib monotherapy for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC) saw a 68 percent objective response rate (ORR), and also showed that safety analysis of all 531 patients enrolled to LIBRETTO-001, selpercatinib was well-tolerated, with only 9 patients (1.7%) discontinuing therapy due to treatment-related toxicity.